CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBC leniolisib Activated phosphoinositide 3 kinase delta syndrome Suspended
TBC exagamglogene autotemcel Sickle cell disease (SCD) Active
TBC rozanolixizumab Generalized myasthenia gravis (gMG) Active
TBC zolbetuximab Gastric or gastroesophageal junction (GEJ) adenocarcinoma Active
TBC tarlatamab Extensive stage small cell lung cancer Active
TBC garadacimab Hereditary angioedema (HAE) Active
TBC ravulizumab Paroxysmal nocturnal hemoglobinuria. Withdrawn
TBC halobetasol propionate and tazarotene Psoriasis, moderate to severe plaque Withdrawn
TBC etonogestrel Prevention of pregnancy Withdrawn
TBC filgotinib Arthritis, Rheumatoid Withdrawn
TBC daprodustat Anemia due to chronic kidney disease Withdrawn
TBC ferumoxytol Iron deficiency anemia Withdrawn
TBC belantamab mafodotin, bortezomib, dexamethasone Previously treated multiple myeloma Pending
TBC belantamab mafodotin, pomalidomide, dexamethasone Previously treated multiple myeloma Pending
TBC avapritinib Advanced Systemic Mastocytosis Active
TBC exagamglogene autotemcel Transfusion-dependent β-thalassemia Active
TBC trofinetide Rett syndrome (RTT) Pending
TBC Darunavir / cobicistat HIV infection Withdrawn
TBC donanemab Alzheimer's disease Active
TBC momelotinib Myelofibrosis Active
TBC Efanesoctocog alfa congenital factor VIII deficiency Received
TBC delgocitinib Chronic hand eczema Pending
TBD iptacopan paroxysmal nocturnal hemoglobinuria (PNH) Active
TBD Cabozantinib Withdrawn
TBD Rituximab Cancelled
Last Updated : September 20, 2024